In the current study, we evaluated the clinical utility of a multiple variable prostate cancer biomarker panel test on the analysis of 777 patients assessed the combinatorial power of filamin-A (FLNA), age, and prostate volume in predicting separation of BPH versus PCa diagnoses compared to PSA. Here, FLNA is linked to benign prostatic hyperplasia.